- Important step for Tetra to ensure meaningful collaboration and patient engagement in research.
OTTAWA, ON, July 22, 2021 – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today it has engaged Christine Caron as Patient Partner to support significant and active collaboration in research, knowledge translation, and patient engagement within the pain and Sepsis communities.
Guy Chamberland, CEO and Chief Regulatory Officer of Tetra commented “We are very pleased to have Ms. Caron join the Tetra team as its first Patient Partner. Christine will provide valuable insights about living with post-infection and pain, due to her amputations because of Sepsis, that may validate or change the direction of concepts we explore, such as targeting outcomes that are important to patients.”
“Tetra is developing a patient centric approach to better reflect patients’ needs and preferences along its clinical development programs. Tetra’s drug products, such as QIXLEEF™, are intended to improve pain management and quality of life, concepts that are highly subjective and directly related to the patient’s reality. I’m grateful to Christine who willingly accepted to be our first Patient Partner,” commented Aurelia De Pauw, Senior VP Clinical Programs/Medical Affairs.
Ms. Caron will be involved in reviewing and commenting on informed consent forms, questionnaires, or interview guides related to Tetra’s clinical trials. She will also be assisting with knowledge translation planning and with sharing Tetra’s research results with key audiences, such as the Amputee Coalition of Canada, Sepsis Canada, Global Sepsis Alliance, and Sepsis Alliance.
“We need to advocate and educate, because Sepsis does not discriminate!” commented Ms. Caron. “I am thrilled to join Tetra in the fight against Sepsis by contributing to advocacy, health literacy, knowledge transfer, and to support families who share this journey. I also believe in the therapeutic benefits of cannabis and will advocate to bring safer pain management prescription alternatives to patients”.
About Christine Caron
In 2013, Ms. Caron lost multiple limbs after a dog bite sent her into Septic Shock. Since then, she has been committed to raising awareness about Sepsis and connecting with survivors and their families. Christine has a strong professional background in science and health communications, which has served her well in her recent roles as Patient Advisor with the Canadian Sepsis Foundation, Director on the Board of the Amputee Coalition of Canada, and as a special guest speaker at university level functions and multiple conferences on Sepsis. You may learn more about Christine’s story by visiting the Global Sepsis Alliance page, here.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com